ArmaGen Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ArmaGen Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10888
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a clinical stage biotechnology company that develops novel therapies for the treatment of neurological disorders. The company’s pipeline products include AGT-181, AGT-182, AGT-183, AGT-184, AGT-187, AGT-115, AGT-190, AGT-110 and AGT-160. Its products are used for the treatment of neurological symptoms of lysosomal storage diseases. ArmaGen’s products are also used to treat neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s technology platform solution targets recombinant proteins, and therapeutic monoclonal antibodies to the brain. ArmaGen is headquartered in Calabasas, California, the US.

ArmaGen Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ArmaGen Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
Partnerships 12
ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12
Licensing Agreements 13
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13
ArmaGen Inc – Key Competitors 14
ArmaGen Inc – Key Employees 15
ArmaGen Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Jan 19, 2017: ArmaGen Appoints Mathias Schmidt, Ph.D., as Chief Executive Officer 17
Product Approvals 18
Nov 30, 2017: ArmaGen’s AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I) 18
Clinical Trials 19
Feb 08, 2018: ArmaGen’s AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I 19
Feb 16, 2017: ArmaGen Reports Preliminary Evidence of Cognitive Improvement in Children with Hurler Syndrome (MPS I) Treated with AGT-181 21
Feb 07, 2017: ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
ArmaGen Inc, Pharmaceuticals & Healthcare, Key Facts 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ArmaGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13
ArmaGen Inc, Key Competitors 14
ArmaGen Inc, Key Employees 15

List of Figures
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ArmaGen Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Sumitomo Heavy Industries Ltd (6302)
    Sumitomo Heavy Industries Ltd (6302) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Territorial Generating Company #2 (TGKB)-エネルギー分野:企業M&A・提携分析
    Summary Territorial Generating Company #2 (TGC-2) is a power generating company. The company produces and transmits electricity, as well as heat, such as steam and hot water. TGC-2 through its subsidiaries offers its products and services to customers located in Arkhangelsk, Vologda, Kostroma, Novgo …
  • Comstock Resources Inc (CRK):企業の財務・戦略的SWOT分析
    Summary Comstock Resources Inc (Comstock) is an oil and gas company. It acquires, develops, explores and produces oil and natural gas properties. The company provides oil and gas operations such as Eagle ford Shale, Haynesville Shale and Bakken Shale in North Dakota and Montana; and North Louisiana, …
  • Entertainment One Ltd.:企業のM&A・事業提携・投資動向
    Entertainment One Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Entertainment One Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Engie SA (ENGI)-エネルギー分野:企業M&A・提携分析
    Summary Engie S.A. (Engie), formerly GDF Suez S.A., is an electric utility, which generates and distributes electricity and natural gas. It generates electricity using various sources including hydro, wind, solar, biomass, geothermal, nuclear, coal and fuel oil. The company supplies, distributes, tr …
  • JSC Gazprom Neft:企業の戦略・SWOT・財務情報
    JSC Gazprom Neft - Strategy, SWOT and Corporate Finance Report Summary JSC Gazprom Neft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Xylem Inc (XYL)-エネルギー分野:企業M&A・提携分析
    Summary Xylem Inc. (Xylem) is a water technology company that designs, manufactures, and service engineered technologies for water industry. The company’s products portfolio includes testing equipment; filtration, disinfection and biological treatment equipment; controls and systems; and water and w …
  • Union des Groupements d’Achats Publics:企業の戦略的SWOT分析
    Union des Groupements d'Achats Publics - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • ifa systems AG (IS8):企業の財務・戦略的SWOT分析
    ifa systems AG (IS8) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Qinetiq Group Plc:企業の戦略・SWOT・財務分析
    Qinetiq Group Plc - Strategy, SWOT and Corporate Finance Report Summary Qinetiq Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Yantai Dongcheng Pharmaceutical Group Co Ltd (002675):製薬・医療:M&Aディール及び事業提携情報
    Summary Yantai Dongcheng Pharmaceutical Group Co Ltd (Yantai Dongcheng Pharma), formerly Yantai Dongcheng Biochemicals Co Ltd, is a developer, manufacturer, and marketer of biochemical API, chemical synthetic drugs, and Chinese medicines. The company offers its products under categories including he …
  • Atlas Genetics Ltd-医療機器分野:企業M&A・提携分析
    Summary Atlas Genetics Ltd (Atlas Genetics) is an in vitro diagnostics company that offers decentralised, near-patient and point of care testing services. The company develops and offers diagnostic platforms such as io system and callisto system. Its io system is a diagnostic instrument and disposab …
  • Sujana Universal Industries Ltd. (SUJANAUNI):企業の財務・戦略的SWOT分析
    Sujana Universal Industries Ltd. (SUJANAUNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Amazon Web Services Inc:企業の戦略・SWOT・財務分析
    Amazon Web Services Inc - Strategy, SWOT and Corporate Finance Report Summary Amazon Web Services Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Yandex NV (YNDX):企業の財務・戦略的SWOT分析
    Yandex NV (YNDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Starbucks Corp (SBUX):企業の財務・戦略的SWOT分析
    Starbucks Corp (SBUX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Medivir AB (MVIR B):企業の財務・戦略的SWOT分析
    Summary Medivir AB (Medivir) is a pharmaceutical company. It is engaged in drug discovery and development of treatments for cancer.The company offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid le …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Allscripts Healthcare Solutions Inc (MDRX):医療機器:M&Aディール及び事業提携情報
    Summary Allscripts Healthcare Solutions Inc (Allscripts), formerly Allscripts-Misys Healthcare Solutions, Inc., is a provider of healthcare information technology solutions. The company’s major solutions include Electronic Health Records (EHR), Financial Management Solutions, Population Health Manag …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆